Survodutide Weight Loss: What the Trials Show So Far
Survodutide is still in trials. People lost 16.6% of their body weight on average in its main study so far.
- Average weight lost
- 16.6%
- Trial length
- 76 weeks
Survodutide overview
Based on the efficacy estimand, weight loss at 76 weeks is shown as a percentage of body weight (SYNCHRONIZE-1, vs 3.2% placebo).
Sources: boehringer-ingelheim.com.
Approved choices and trial results
Outside a trial, Survodutide cannot be prescribed right now. These approved medicines can produce the following results in their main weight trials:
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg weekly | 14.9% | 2.4% | 68 | Adults with obesity or overweight, without diabetes |
| OASIS 4 | Wegovy pill 25 mg daily | 13.6% | 2.4% | 64 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | 20.9% | 3.1% | 72 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-2 | Tirzepatide 15 mg weekly | 14.7% | 3.2% | 72 | Adults who have type 2 diabetes and also have obesity or are overweight |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Adults who have type 2 diabetes and also have obesity or are overweight |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults who have type 2 diabetes and also have obesity or are overweight |
| STEP 2 | Semaglutide 2.4 mg weekly | 9.6% | 3.4% | 68 | Adults who have type 2 diabetes and also have obesity or are overweight |
Sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed).